نتایج جستجو برای: protein tyrosine phosphatase non

تعداد نتایج: 2476159  

2003
Jin Hee Ahn Sung Yun Cho Jae Du Ha Seung Kyu Kang Sun Ho Jung Hye-Min Kim Sung Soo Kim Kwang Rok Kim Hyae Gyeong Cheon Sung-Don Yang Joong-Kwon Choi

As most intracellular signaling takes place via cascades of phosphorylation and dephosphorylation of tyrosines, protein tyrosine phosphatases have emerged as new and promising targets. Among them, protein tyrosine phosphatase 1B (PTP1B) negatively regulates insulin signaling by dephosphorylation of key tyrosine residues within the regulatory domain of the β-subunit of the insulin receptor, ther...

Journal: :The Journal of Experimental Medicine 2004
Karen Badour Jinyi Zhang Fabio Shi Yan Leng Michael Collins Katherine A. Siminovitch

Involvement of the Wiskott-Aldrich syndrome protein (WASp) in promoting cell activation requires its release from autoinhibitory structural constraints and has been attributed to WASp association with activated cdc42. Here, however, we show that T cell development and T cell receptor (TCR)-induced proliferation and actin polymerization proceed normally in WASp-/- mice expressing a WASp transgen...

Journal: :Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996
J P Medema G J Pronk A M de Vries-Smits R Clark F McCormick J L Bos

We have used two approaches to identify possible substrates of the insulin receptor (IR) tyrosine kinase. First, we used a potent tyrosine phosphatase inhibitor, phenylarsine oxide (PAO), which is reported to be specific for the insulin-induced signal transduction route, to augment tyrosine phosphorylation. Second, we used src homology 2 (SH2) domains fused to glutathione S-transferase as high ...

2016
Shudi Xu Tao Wang Zhiwei Yang Ying Li Weijie Li Ting Wang Shan Wang Lintao Jia Shengli Zhang Shengqing Li

Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have emerged as first-line drugs for non-small cell lung cancers (NSCLCs). However, the resistance to TKIs represents the key limitation for their therapeutic efficacy. We found that miR-26a was upregulated in gefitinib-refractory NSCLCs; miR-26a is downstream of EGFR signaling and directly targets and silences p...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید